Skip to content

Study on the comprehensive management of drug treatment for cancer patients and its influence on ADR in patients

Study on the comprehensive management of drug treatment for cancer patients and its influence on ADR in patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092249
Enrollment
Unknown
Registered
2024-11-13
Start date
2024-10-10
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Experimental group:the comprehensive Management of Drug treatment
Control group:Conventional treatment

Sponsors

Qingdao Chengyang District People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age: 18-80 years old, meeting the diagnostic criteria for lung cancer, gastric cancer, esophageal cancer, liver cancer, breast cancer; The patient voluntarily participates and signs an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Associated with other serious underlying diseases, such as heart, lung, kidney dysfunction, etc; 2.Incomplete clinical data; 3.Patients with mental disorders; 4.History of adverse drug reactions;

Design outcomes

Primary

MeasureTime frame
Types and quantities of adverse reactions;

Secondary

MeasureTime frame
Severity of gastrointestinal reactions;Severity of bone marrow suppression;

Countries

China

Contacts

Public Contactzhouguo wei

Qingdao Chengyang District People's Hospital

wrxd3@qq.com+86 532 58000380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026